2min chapter

Yet Another Value Podcast cover image

Caligan Partners' Dave Johnson on MorphoSys' $MOR change from royalty play to traditional biotech

Yet Another Value Podcast

CHAPTER

The Risk-Adjusted Value of Pelagorasa

The risk-adjusted value of Pelagorasa is about $45 per share. The way that we got there was, in pricing is for these drugs, it's all in the multiple teams of thousands of dollars per month. We said, hey, what if they only get half the patients that they're newly diagnosed in? What if we only get the same duration of responses they get with rectilitinum? Usually, your discontinuation rate with jackifies about 30% in the first year and then it falls off,. 20% in the second year, and then it kind of falls off a cliff after that.

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode